Michelmore

Maravai LifeSciences Announces Preliminary Unaudited First Quarter Revenues and Income From Operations Range

Retrieved on: 
Monday, April 5, 2021

Maravai intends to provide its full financial results for the first quarter after the market close on Monday, May 10, 2021.

Key Points: 
  • Maravai intends to provide its full financial results for the first quarter after the market close on Monday, May 10, 2021.
  • Until that time, the preliminary revenue results described in this press release are estimates only and are subject to revision.
  • When the Company reports its first quarter results, it also expects to provide updated financial guidance for full year 2021.
  • Contact Information: Media Contact: Sara Michelmore MacDougall +1 781-235-3060 [email protected] Investor Contact: Deb Hart Maravai LifeSciences + 1 858-988-5917 [email protected]

Maravai LifeSciences Announces March 2021 Investor Conference Schedule

Retrieved on: 
Monday, March 1, 2021

OnMarch 3, 2021, Carl Hull, Chief Executive Officer, is scheduled to present at the Cowen Health Care Conference at10:20 a.m. PT.

Key Points: 
  • OnMarch 3, 2021, Carl Hull, Chief Executive Officer, is scheduled to present at the Cowen Health Care Conference at10:20 a.m. PT.
  • OnMarch 23, 2021, Hull will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum at8:30 a.m. PT.
  • A live webcast of the presentations will be available to all interested parties on the Maravai Lifesciences investor relations website at http://investors.maravai.com .
  • Contact Information: Media Contact: Sara Michelmore MacDougall +1 781-235-3060 [email protected] Investor Contact: Deb Hart Maravai LifeSciences + 1 858-988-5917 [email protected]

Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Complement Therapeutics

Retrieved on: 
Tuesday, January 12, 2021

With our strong capital position, highly experienced leadership team and precision medicine approach, we are rapidly advancing our portfolio and are poised to drive value in 2021 and beyond.

Key Points: 
  • With our strong capital position, highly experienced leadership team and precision medicine approach, we are rapidly advancing our portfolio and are poised to drive value in 2021 and beyond.
  • A live webcast of the event can be accessed under the Events & Presentations section on the Investors page at www.annexonbio.com.
  • Annexon is deploying a disciplined, biomarker-driven development strategy designed to identify patients, and to measure target engagement and response to treatment.
  • Investor Contacts: Jennifer Lew, Chief Financial Officer Annexon Biosciences [email protected] Sara Michelmore [email protected] Media Contacts: Miriam Mason Annexon Biosciences [email protected] Caroline Rufo, Ph.D. [email protected]

Annexon to Present at the J.P. Morgan 39th Annual Healthcare Conference

Retrieved on: 
Tuesday, January 5, 2021

A live webcast of the event can be accessed under the Events & Presentations section on the Investors page at www.annexonbio.com .

Key Points: 
  • A live webcast of the event can be accessed under the Events & Presentations section on the Investors page at www.annexonbio.com .
  • A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
  • Annexon is deploying a disciplined, biomarker-driven development strategy designed to identify patients, and to measure target engagement and response to treatment.
  • Investor Contacts: Jennifer Lew, Chief Financial Officer Annexon Biosciences [email protected] Sara Michelmore [email protected] Media Contacts: Miriam Mason Annexon Biosciences [email protected] Caroline Rufo, Ph.D. [email protected]